CELL THERAPY & STEM CELLS
Streamlining the development of regenerative therapies
FROM REACTIVE TO REGENERATIVE MEDICINE
Newly developed therapies, such as stem cell therapy, are shifting the field of medicine from simply treating symptoms to curing diseases altogether. For over 30 years, stem cell therapies have been widely used to treat leukemia and lymphoma patients by transplanting hematopoietic stem cells from healthy donors. The therapy, however, has its limitations, including finding matching donors and dealing with tissue rejection. New generation autologous cell therapies, like CAR T-cell therapy for cancer, overcome these limitations by using a patient’s own cells, but the process of taking, modifying and transplanting a patient’s cells remains costly and labor intensive.
THE ERA OF INDUCED PLURIPOTENT STEM CELL THERAPY
Human induced pluripotent stem cells (iPSCs) have changed regenerative medicine with their capability to differentiate into different tissues. Although human iPSCs are already used in autologous therapies, the next breakthrough will be to develop certified iPSCs for off-the-shelf treatment. Reducing immunogenicity of iPSCs via human leukocyte antigen (HLA) depletion that facilitate creating GMP-grade master cell banks for the mass production of cells, while lowering manufacturing costs of allogenic therapies.
HUMAN iPSC MASTER CELL BANKS
We offer an extensive product portfolio that streamlines time-consuming steps and improves quality control in your iPSC workflows.
COMPREHENSIVE iPSC STATUS MONITORING
Culturing and passaging of iPSCs is a crucial step that affects the quality of the cells. CASY, our cell counter & analyzer, provides comprehensive insights into iPSC health, viability and aggregation state in one easy measurement and with no additional dyes required. CASY streamlines your sample preparation with fast and easy-to-use cell counting and analyzing software and facilitates optimization of your experiment protocols.
SINGLE-CELL CLONING FOR GENERATING CLINICAL-GRADE hiPSCs TO MEET REGULATORY REQUIREMENTS
Developing immunologically compatible iPSCs requires several rounds of cloning after transfection. The traditional limiting dilution method for isolating single cells is time consuming and flow cytometry negatively affects the viability of highly sensitive iPSCs. CYTENA’s new F.SIGHT™ 2.0 single-cell dispenser with fluorescent sorting assures clonality through image-based cell isolation in under two minutes and prevents cell loss with the Cell Focusing feature.
The UP.SIGHT™, with a probability of clonality >99.99%, fulfills required regulatory expectations. Double assurance of iPSC clonality is achieved through nozzle images and 3D Full Well Imaging. Highly efficient and gentle cell sorting with the EASY.ON cartridge maintains the viability of iPSCs.
TRACKING CELL GROWTH EFFORTLESSLY
The viability of clonal iPSCs is another hurdle for stem cell development workflows. The CELLCYTE X™, CYTENA’s high-throughput live cell imaging system, lets you effortlessly monitor growing colonies inside your incubator, improving cell viability over the course of an experiment. The instrument can run up to 6 plates concurrently and enables you to rewind and replay images, providing a full picture of the iPSC workflow. With the CELLCYTE X, determine the right timepoint for passaging and analysis for the iPSC master cell banks.
STEM CELL RESEARCH WORKFLOW
1. Culturing iPSCs
2. Counting & passaging
3. Transfection & gentle single cell cloning
5. Cell banking
Featured products pages and resources
- Flahou C, Morishima T, Takizawa H, Sugimoto N. Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Frontiers in Immunology. 2021; 12: 1071. DOI:10.3389/fimmu.2021.662360.
- Murata K, Ikegawa M, Minatoya K, et al. Strategies for immune regulation in iPS cell-based cardiac regenerative medicine. Inflammation and Regeneration. 2020; 40(1): 36. DOI:10.1186/s41232-020-00145-4.